Core One Labs Inc. (OTCQB:CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN:A3CSSU) announced that its wholly-owned subsidiary, Awakened Biosciences Inc. has successfully completed the first synthetic production of psilocin at the GMP manufacturing facility of its recently acquired GMP Drug Inc.
"Awakened's successful first synthetic production of psilocin at the GMP Drug Inc. facilities is a major accomplishment for Core One, and it lays the groundwork for the large-scale production of psychedelic compounds at a GMP certified facility. As Core One looks to become a major supplier of psychedelic compounds, it is important that we demonstrate the company's ability to execute at each stage of our strategic process. This achievement brings us one step closer to our long-term goal of supplying the medical community with affordable, API grade, psychedelic compounds," stated Joel Shacker CEO of the company.
The successful synthesis of psilocin advances previous work conducted by Awakened, where its team of scientist witnessed success in the ability to produce a precursor that can be efficiently converted into psilocin, with further conversion into commercially viable psilocybin. The confirmation of Awakened's synthetic production methods is also extremely important for the future developments of the company, as it lays the path upon which additional research can be conducted. As such, Awakened will look to replicate methods used in the successful synthetic production of psilocin and subsequent conversion to psilocybin, for future production of dimethyltryptamine and its intermediates, and other psychedelic prodrugs and compounds.
The research and resulting production have been led by CEO of Awakened, Dr. Tony Durst, who is also an emeritus professor at the University of Ottawa, and a renowned specialist in medicinal and natural product chemistry. Dr. Durst's previous successes are many and include the awarding of 14 successful patents, of which he was co-inventor.
Photo by Louis Reed on Unsplash
Related News
Across The Globe: Psychedelic Trials To Treat Late-Stage Cancer, Alzheimer's Begin
Core One实验室公司(OTCQB：CLABF)(CSE：COOL)(法兰克福：LD6)(WKN：A3CSSU)宣布其全资子公司，觉醒的生物科学公司。有成功地完成了首个裸鼠毒素的合成生产在其最近收购的GMP制造工厂GMP药品公司。
Core One的一项重大成就是在GMP制药公司的设施中成功地首次成功合成了裸鼠毒素，并为在GMP认证的设施中大规模生产迷幻化合物奠定了基础。随着Core One希望成为迷幻化合物的主要供应商，我们必须证明该公司在我们战略过程的每个阶段都有执行的能力。这一成就使我们离向医学界提供负担得起的、原料药级别的迷幻化合物的长期目标又近了一步乔尔·谢克公司的首席执行官。
裸盖菇素的成功合成推进了之前由觉醒公司进行的工作，该公司的科学家团队见证了成功地生产出一种可以有效转化为裸盖菇素的前体，并进一步转化为商业上可行的裸盖菇素。确认觉醒的合成生产方法对公司未来的发展也是极其重要的，因为它为进一步的研究奠定了基础。因此，觉醒公司将寻求复制成功合成裸盖菇素并随后转化为裸盖菇素的方法，用于未来生产二甲基色胺及其中间体，以及其他迷幻前药和化合物。
这项研究和由此产生的成果一直由觉醒的首席执行官领导，Tony·德斯特博士他也是渥太华大学的荣誉退休教授，也是一位著名的药物和天然产品化学专家。德斯特博士之前的成功很多，包括授予14项成功的专利，他是这些专利的共同发明人。
路易·里德在Unspash上拍摄的照片
相关新闻
全球：治疗晚期癌症的迷幻试验，阿尔茨海默氏症开始
